Immunoglobulin for acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT)

Wyndham, A, Vogan, A, Newton, S, Schubert, C
Record ID 32018000650
Original Title: Application 1565
Authors' results and conclusions: Trials were reported for patients with chronic lymphocytic leukaemia (CLL), multiple myeloma (MM) and those who underwent haemopoietic stem cell transplantation (HSCT). However, no adequate randomised trials were identified in patients with acute leukaemia, Non-Hodgkin lymphoma (NHL) or 'other haematological malignancies'. It was however considered plausible that similar outcomes would be observed in acute leukaemia, NHL and 'other haematological malignancies', assuming the patients satisfied the criteria for hypogammaglobulinaemia and history of infections. It was not possible to evaluate the claim that IgG with or without antibiotics is superior to No IgG with or without antibiotics. The clinical evidence in the included studies support a claim of superior efficacy but inferior safety for IgG compared to no IgG (with antibiotic use defined as part of supportive care).
Project Status: Completed
Year Published: 2019
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Australia
MeSH Terms
  • Hematopoietic Stem Cell Transplantation
  • Multiple Myeloma
  • Lymphoma, Non-Hodgkin
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia
  • Immunoglobulin G
Organisation Name: Adelaide Health Technology Assessment
Contact Address: School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
Contact Email:
Copyright: Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.